astrazeneca plc-spons adr
(AZN:New York Consolidated)
Transactions by ASTRAZENECA PLC-SPONS ADR (AZN) in the last 6 months
AstraZeneca PLC (LSE:AZN) acquired Corridor Pharmaceuticals, Inc. from Acidophil, LLC, MedImmune Ventures, Inc. and other investors in 2014.
Domain Associates, L.L.C.
Domain Partners VI, L.P.
MedImmune Ventures, Inc.
Osage Partners LLC
Moderna LLC announced that it will receive $502,168,634 in funding on December 19, 2014. The company will issue series E preferred units in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
As of January 5, 2015, the company received $446,069,409 from 43 investors including new investors Viking Global Investors LP, Invus, RA Capital Management, and Wellington Management Company, LLP. The transaction included participation ...
RA Capital Management, LLC
The Invus Group, LLC
Viking Global Investors L.P.
Wellington Management Company LLP
Aegerion Pharmaceuticals, Inc. (NasdaqGS:AEGR) entered into a definitive agreement to acquire Myalept from AstraZeneca PLC (LSE:AZN) for approximately $330 million on November 5, 2014. The transaction does not include the transfer of any AstraZeneca employees or facilities. The transaction is subject to closing conditions, including the receipt of Hart-Scott-Rodino antitrust clearance from the US Federal Trade Commission. The companies expect the transaction to complete ...
|AbbVie Inc||$56.86 USD||-3.41|
|Biogen Idec Inc||$425.61 USD||+11.48|
|Celgene Corp||$120.71 USD||+1.14|
|Eli Lilly & Co||$70.59 USD||-0.06|
|Novo Nordisk A/S||kr318.00 DKK||+2.40|
|View Industry Companies|